LAVAL, QC, Canada (August 15, 2018) — Altasciences announced today that it has signed a definitive agreement to acquire the preclinical testing business of SNBL U.S.A. The transaction is expected to be completed at the end of September. This acquisition will add comprehensive preclinical safety testing services to Altasciences’ current full-service clinical and bioanalytical offerings. Altasciences will now support all crucial steps in early-stage drug development, from lead candidate selection to proof of concept. This acquisition is an integral part of the company’s strategic growth plan to address the ever-changing outsourcing challenges of biopharmaceutical companies across the globe.
“Expanding our services to include preclinical safety testing was a natural progression for Altasciences and the perfect complement to our current offering. With the extensive preclinical and clinical experience of our management and scientific teams, we knew we had a unique opportunity to work towards creating a strategic combination of services that would make the outsourcing process for our clients easier and more cost effective, while shortening the timeline to proof of concept,” stated Chris Perkin, Chief Executive Officer of Altasciences.
Transferring data, projects and/or methodologies between CROs, or between different groups within a multi-service CRO, can take time, is prone to error, and can lead to prolonged R&D timelines. Altasciences is looking to address these challenges through the integration of strategic acquisitions, such as the SNBL U.S.A. preclinical business. The result will be a fully integrated offering, improving ‘speed and ease’ throughout early stage development by carrying best practices across services along with the addition of platforms that support integrated data capture and program management, allowing for quicker, more proactive development timeline adjustments and decision making to improve R&D efficiency for biopharmaceutical customers.
“Our customers have told us that they see value in carrying learnings from preclinical studies through to trial design decisions in the early phases of clinical development. Our strength in Phase I trial conduct and support, our extensive bioanalytical capabilities and our track record of customer service are the perfect foundation for adding preclinical safety testing capabilities.” added Chris Perkin.
Altasciences Clinical Research is a mid-size contract research organization that encompasses Algorithme Pharma in Montreal, QC, Vince & Associates Clinical Research in Overland Park, KS, and Algorithme Pharma USA in Fargo, ND, with an overall company focus on supporting early-stage drug development. With over 25 years of industry experience, Altasciences provides clinical services to an international customer base of biopharmaceutical companies. Altasciences’ full-service solutions offering in this critical stage of drug development includes clinical pharmacology, medical writing, biostatistics, data management and bioanalysis.
For more information